What is HC Wainwright’s Forecast for ATNM FY2026 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright lowered their FY2026 EPS estimates for shares of Actinium Pharmaceuticals in a report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($1.09) for the year, down from their previous forecast of ($0.75). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2027 earnings at ($0.80) EPS and FY2028 earnings at ($0.86) EPS.

Separately, Stephens reiterated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $4.50.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE ATNM opened at $0.99 on Thursday. Actinium Pharmaceuticals has a 1 year low of $0.95 and a 1 year high of $1.95. The firm’s 50 day moving average price is $1.14 and its 200 day moving average price is $1.35. The firm has a market cap of $30.88 million, a P/E ratio of -0.71 and a beta of -0.31.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mayport LLC purchased a new position in shares of Actinium Pharmaceuticals during the 3rd quarter worth about $35,000. AM Investment Strategies LLC purchased a new stake in Actinium Pharmaceuticals in the fourth quarter valued at approximately $40,000. Qube Research & Technologies Ltd acquired a new position in Actinium Pharmaceuticals during the second quarter worth approximately $70,000. Bailard Inc. acquired a new position in Actinium Pharmaceuticals during the fourth quarter worth approximately $79,000. Finally, Squarepoint Ops LLC purchased a new position in Actinium Pharmaceuticals during the fourth quarter worth approximately $89,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.